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Abstract
Background
Colorectal cancer (CRC) is one of the commonest cancers associated with diverse progno-
sis times in different parts of the world. Despite medical interventions, the overall clinical out-
comes and survival remains very poor for most patients in developing countries. This study
therefore investigated the survival rate of colorectal cancer and its prognostic factors among
patients at Komfo Anokye Teaching Hospital, Ghana.
Methodology
In this retrospective cohort study, a total of 221 patients diagnosed with CRC from 2009 to
2015 at the Surgical and Oncological units of Komfo Anokye Teaching Hospital (KATH),
Kumasi, Ghana were employed. The survival graphs were obtained using the Kaplan–Meier
method and compared by the Log-rank test. Cox regression analysis was used to assess
prognostic factors. All analyses were performed by SPSS version 22.
Results
The median survival time was 15 months 95% CI (11.79–18.21). The overall survival rate
for CRC over the 5 years period was 16.0%. The survival rates at the 1st, 2nd, 3rd, 4th and 5th
years were 64% 95% CI (56.2–71.1), 40% 95% CI (32.2–50.1), 21% 95% CI (11.4–30.6)
16% 95% CI (8.9–26.9) and 16% 95% CI (7.3–24.9). There was a significant difference in
the survival rate of colorectal cancer according to the different stages (p = 0.0001). Family
history [HR = (3.44), p = 0.029)], Chemotherapy [HR = (0.23), p = <0.0001)], BMI [HR =
(1.78), p = 0.017)] and both chemo/radiotherapy (HR = (3.63), p = 0.042)] were the signifi-
cant social and clinical factors influencing the overall survival. Pathological factors such as
TNM tumour stage (p = 0.012), depth of tumour invasion (p = 0.036), lymph node metastasis
(p = 0.0001), and distance metastasis (p = 0.001) were significantly associated with overall
survival.
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Conclusion
The study has clearly demonstrated that survival rate for CRC patients at KATH, Ghana is
very low in a 5 years period. This is influenced by significant number of clinical and patholog-
ical prognostic factors. Identification of prognostic factors would be a primary basis for early
prediction and treatment of patients with colorectal cancer.
Introduction
Globally, colorectal cancer is one of the commonest cancers and in the western countries; it is the
second leading cause of cancer mortality. [1]. The difference in survival rates observed in various
clinical trials maybe due to the variations in patient’s characteristics and prognostic factors [2].
Survival of colorectal cancer has improved dramatically over the last decade as a result of the
invention of new drugs and targeted therapies. [3]. However, enormous disparities in colorectal
cancer survival exist within regions and across the global [4, 5]. These differences are not easily
understood, although most of the disparities in CRC survival can be attributed to variation in the
accessibility to treatment and diagnostics [5]. In addition, molecular analyses performed so far
indicates that the pathogenesis of all CRCs varies at different stage tumours. Even for individual
patients with same stage tumours, response to treatment and long term prognosis varies[6].
Over the past years, several research groups have suggested numerous factors associated
with the survival of CRC patients.[7, 8]. However, the extent of tumour infiltration to the
bowel wall, adjacent lymph node metastases and distant metastasis are the major contributing
factors [9]. Although, various studies [10, 11] have reported a strong correlation between colo-
rectal cancer stage and its prognosis, it has also been argued in other studies [10, 12] that the
prognosis for a patient with colorectal cancer is much influenced by factors relating to patients
characteristics and the tumour but not just the anatomical extension of the tumour.
Additionally, other studies have also showed that the initial treatment administered, body mass
index (BMI), marital status, tumour grade, tumour size and pathologic stage of tumour are signifi-
cantly associated with the survival of CRC patients [5, 13]. Recent studies have shown that the sur-
vival of CRC in sub-Saharan African is very low due to late presentations and lack of modern
specialized systems for treatment [14]. In Ghana, the number of new cases of colorectal cancer
has increased by 8- fold per year from an average of 4.1 new cases in 1960s to an average of 32.6
new cases currently [15, 16]. In 2010, Dakubo et al reported a crude incidence rate of 11.18 per
100,000 populations in both sexes. Moreover, Laryea et al., (2014) reported a crude incidence and
age standardized incidence of 0.1 and 0.3 per 100,000 population [17]. Some studies have identi-
fied other factors such as helicobacter pylori infection, the dietary component of red meat, beef,
lamb, pork and veal and its processed varieties as the predominant risk factors in Ghana [16, 18,
19]. There is paucity of data on the survival rate of CRC as well as its associated factors in Ghana.
Knowledge of prognostic factors in our population will be the foundation for planning treatment
and predicting the outcome of patients with colorectal cancer. It is thus, against this background
that this study investigated the survival rate of colorectal cancer and its prognostic factors among
patients at Komfo Anokye Teaching Hospital, Ghana.
Methodology
Study design/setting
This was a retrospective cohort study, conducted among CRC patients at the Surgical and
Oncological (S&O) Department of the Komfo Anokye Teaching Hospital. Komfo Anokye
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Teaching Hospital (KATH) is the second largest and a referral teaching hospital located in
Kumasi, the regional capital of the Ashanti region in Ghana. The region has an average total
population of 4,780,380 (Ghana Statistical Service, 2010).
Study population and participants’ selection
A total of 221 cases of CRC, recorded from 2009 to 2015 were retrospectively retrieved from
the medical records of the S & O Department database with a 100% rate of accuracy. Informa-
tion on socio-demographics characteristics, clinical and pathological variables including histo-
logical type, grade of tumour and TNM staging were recorded. Data on type of treatments was
also reviewed. Moreover, BMI based on the patient’s current recorded weight and height since
been diagnosed was also calculated. Smoking history comprised of patients who indicated that,
they had ever smoked or was currently smoking, and alcohol intake also refers to patients who
were currently alcoholics and those who used to be alcoholic.
Inclusion criteria
Records showing complete clinical examination, indicating the presence of malignant tumour
in the large bowel were included.
Exclusion criteria
Patients with other large bowel conditions and histopathological confirmed non-malignant
tumours were excluded.
Follow-up
Patients were contacted during their follow-up visits to the hospital and those who could not
report for review in the hospital were contacted via telephone. Deaths of subjects were con-
firmed via contact with their families and relatives. Survival periods were calculated from the
date of diagnosis to the date of either last follow-up or death. Patients alive at the end of the fol-
low-up and those lost to follow-up were censored either at the last contact or at death.
Fig 1 shows the procedure for the selection of cases for the study.
Statistical analysis
Data entry and analysis were performed using SPSS version 20. Survival analysis was done
using Kaplan–Meier method and the differences in patient survival periods were determined
by employing the log-rank test in relation to socio-demographic and lifestyle characteristics,
and clinical and pathological parameters [Tables 1 and 2]. To determine the prognostic factors
for survival, all variables were tested for their relationship in the Cox-regression model. Pro-
portional hazard (PH) assumptions were initially tested for each model [Tables 3–5] based on
the scaled Schoenfeld residuals. The PH test was not significant for each of the covariates in
each model and the global Schoenfeld test (GST) was not statistically significant for each
model [Table 3; GST: p = 0.481, Table 4; GST: p = 0.186, Table 5; GST: p = 0.216], we therefore
assumed the proportional hazards. Multicollinearity test was done for covariates in each
model, and the variation inflation factor (VIF) value obtained for covariates in each model was
within a range of 1–5 suggesting that there is no multicollinearity. Multivariable Cox regres-
sion analysis was carried using the force entry procedure. The Chi-square value obtained for
the regression model for Table 4 (χ2 = 42.7, p<0.0001) and Table 5 (χ2 = 28.8, p = 0.017) were
statistically significant, however Chi-square value for regression model for Table 3 did not
show significance (χ2 = 15.8, p = 0.328). There were no statistically significant differences
Colorectal cancer survival rates in Ghana
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between patients who were follow-up and those who were not followed in relation to socio-
demographic and lifestyle characteristics, clinical and pathological parameters [S1 Table]. A
p< 0.05 was accepted as statistically significant.
Ethical consideration
Ethical Approval for the study was obtained from the Committee on Human Research, Publi-
cation and Ethics (CHRPE/AP/286/15) of the School of Medical Sciences (SMS), Kwame
Nkrumah University of Science and Technology (KNUST) as well as the Research and Devel-
opment (R&D) Unit of the KATH.
Results
As shown in Fig 2, the median survival time was 15 months 95% CI (11.79–18.21). The survival
rates at the 1st, 2nd, 3rd, 4th and 5th years were 64% 95% CI (56.2–71.1), 40% 95% CI (32.2–
50.1), 21% 95% CI (11.4–30.6) 16% 95% CI (8.9–26.9) and 16% 95% CI (7.3–24.9).
The survival rate was high among patient in stage I: 90% [95% CI (75.5–104.5)], compared
to stage II: 34% [95% CI (5.6–62.4)], stage III: 12% [95% CI (11.9–13.1)] and stage IV (0.0%).
Fig 1. Procedure for the selection of cases for the study.
https://doi.org/10.1371/journal.pone.0209307.g001
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The differences in survival rates among the different cancer stages were statistically significant
(p = 0.0001) [Fig 3].
Table 1 shows the association between socio-demographic and lifestyle characteristics and
CRC survival. There was no statistically significant association between survival and age
(p = 0.241), gender (p = 0.996), marital status (p = 0.464), presence of comorbidities
(p = 0.250), hypertension (p = 0.232), diabetes (p = 0.588), alcohol intake (p = 0.717) and
smoking (p = 0.696). Meanwhile, family history was significantly associated with survival
(p = 0.036).
As shown in Table 2, chemotherapy as a treatment modality was significantly associated
with survival (p = 0.0001). The median survival time of patient who underwent chemotherapy
was higher (30 months) compared to those who did not undergo chemotherapy (11months).
Body mass index (BMI) was also significantly associated with survival (p = 0.036) with
Table 1. Association of socio-demographic and lifestyle characteristics with survival using log rank test.
Variable Frequency (n, %) Median OS (95% CI) (months) P-value
Age (years) 0.241
< 40 40(22.6%) 28(3.5–52.5)
40–49 31(14.0%) 17(5.0–29.0)
50–59 58(26.2%) 14(6.6–21.4)
60–69 43(19.5%) 14(11.5–16.5)
�70 39(17.6%) 20(9.3–30.7)
Gender 0.996
Female 94(42.5%) 15(10.9–19.1)
Male 127(57.5%) 14(8.6–18.2)
Marital Status 0.464
Single 27(12.2%) 28(0.7–55.3)
Married 140(63.3%) 14(11.0–16.9)
Divorced 21(9.50%) 19(17.5–20.5)
Widowed 33(14.9%) 15(1.8–28.2
Family History 0.036
No 205(92.8%) 15(11.5–18.4)
Yes 16(7.2%) —
Presence of Comorbidities 0.250
No 166(75.1%) 15(11.6–18.4)
Yes 55(24.9%) 15(5.5–24.5)
Hypertension 0.232
No 177(80.1%) 17(13.3–20.7)
Yes 44(19.9%) 14(10.0–18.0)
Diabetes 0.588
No 203(91.9%) 15(11.5–18.5)
Yes 18(8.1%) 28(16.3–39.7)
Alcoholic intake 0.717
No 200(90.5%) 15(11.6–18.4)
Yes 21(9.5%) 21(5.8–36.2)
Smoking history
No 210(95.0%) 15(11.9–19.1) 0.696
Yes 11(5.0%) 13(10.6–15.4)
OS = Overall Survival.
https://doi.org/10.1371/journal.pone.0209307.t001
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underweight patients having the least median survival time (11 months). For the pathological
parameters, there was significant difference in the stage of tumour, lymph node metastasis and
distance metastasis with survival (p< 0.05). Stage III and IV tumours had low median survival
time (Stage III = 14 months, IV = 11months) compared to early stage tumours (36 months).
Other parameters such as histological grade (p = 0.332), depth of tumour invasion (p = 0.070)
and tumour location (p = 0.405) were not significantly associated with survival.
Table 3 shows the association of socio-demographic and lifestyle characteristics with sur-
vival. Using cox regression analysis, family history was the only variable that was significantly
associated with survival on both univariate [HR = 0.37, 95% (0.14–0.99); p = 0.049) and multi-
variate analysis [HR = 3.44, 95%CI (0.09–0.88)]. Age, gender, marital status, alcoholic intake
and smoking history were statistically not associated with survival (p>0.05). The odds of sur-
vival decreased as age advanced as shown in the hazard ratios but was not statistically signifi-
cant (p>0.05). Male gender, being widowed, presence of comorbidities and having
hypertension had increased hazard ratios but not statistically significant on both univariate
and multivariate analysis.
Table 2. Association of clinical and pathological parameters with survival using log rank test.
Variable Frequency
(n, %)
Median OS (95%CI) (Months) P-value Variables Frequency
(n, %)
Median OS (95%CI)
(Months)
P-value
Duration of Symptoms (months) 0.567 Tumour Location 0.405
< 6 95(43.0%) 19(13.4–24.6) Colon 75(33.9%) 14(7.3–20.7)
6 to 12 85(38.5%) 14(11.6–16.4) Rectum 108(48.9%) 17(11.2–22.8)
> 12 41(18.6%) 14(10.2–17.7) Anorectum 18(8.1%) 18(0.8–37.9)
Surgery 0.640 Anal 13(5.9%) 12(10.6–13.4)
No 76(34.4%) 15(9.9–20.1) More than one site 7(3.2%) 19(6.6–31.4)
Yes 145(65.6%) 14(8.8–19.2) Histological Grade 0.332
Nature of Operation 0.741 Well differentiated 51(23.1%) 14((0.9–29.8)
Emergency 49(33.8%) 14(8.8–19.2) Moderately differentiated 104(47.1%) 15(11.0–18.9)
Elective 96(66.2%) 19(12.6–25.4) Poorly differentiated 25(11.3%) 30(0.4–73.9)
Chemotherapy 0.0001 Undifferentiated 41(18.6%) 18(15.6–20.4)
No 118(53.4%) 11(8.0–14.0)
Yes 103(46.6%) 30(18.0–42.0) TNM Tumour Stage 0.0001
Radiotherapy 0.402 Stage I 13(6.0%) 48(41–56.5)
No 166(75.1%) 14(9.8–18.2) Stage II 64(29.0%) 36 (15.2–56.7)
Yes 55(24.9%) 17(13.1–20.8) Stage III 89(40.3%) 14 (11.1–16.9)
Chemo-radiotherapy 0.587 Stage IV 55(24.9%) 11(6.0–16.0)
No 173(80.1%) 15(11.0–19.0)
Yes 43(19.9%) 15(11.8–18.2) Lymph Node Metastasis 0.0001
BMI Categories 0.036 N0 78(35.3%) 36(21.4–50.6)
Underweight 77(34.8%) 11(5.3–16.7) N1 88(39.9%) 12(9.5–14.5)
Normal 90(40.7%) 18(9.7–26.3) N2 55(24.9%) 15(10.1–19.9)
Overweight 32(14.5%) 26(15.2–36.8) Distant Metastasis 0.0001
Obese 22(10.0%) 23(11.3–34.7) M0 68(21.7%) 19(12.0–25.9)
Depth of Tumour Invasion M1 173(78.3%) 11(6.0–15.9)
T2 18(8.2%) 28(15.1–40.9)
T3 84(38.0%) 14(5.2–22.8)
T4 119(53.8%) 14(10.7–18.7)
OS = Overall Survival, BMI = Body Mass Index, P<0.05 = statistically significant.
https://doi.org/10.1371/journal.pone.0209307.t002
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Table 4 shows the association between clinical factors and survival using cox regression
analysis. In both univariate and multivariate analysis chemotherapy (p = 0.0001) and being
underweight (p< 0.05) were significant prognostic factors in colorectal cancer survival. Che-
motherapy was associated with high odds of survival (HR: 0.38 (0.25–0.57) whereas having
chemo radiotherapy (HR: 3.63(1.05–12.59) and being underweight (HR: 1.74(1.11–2.72) were
associated with decrease odds of surviving. Meanwhile, treatment with both chemo and radio-
therapy (p = 0.042) were significant prognostic factors for CRC survival after multivariate anal-
ysis. Duration of symptoms, surgery, nature of operation and having radiotherapy were not
statistically associated with survival (p> 0.05).
The association between pathological factors and survival using cox regression analysis is
shown in Table 5. Stage of tumour, depth of tumour invasion, lymph node metastasis and
Table 3. Association of socio-demographics and lifestyle characteristics with survival using Cox regression analysis.
Univariate Analysis Multivariate Analysis
Variables HR 95% CI P-value HR 95% CI P-value
Age
< 40 1
40–49 0.51 (0.20–1.30) 0.160 0.49 (0.18–1.34) 0.159
50–59 1.28 (0.71–2.33) 0.424 1.27 (0.63–2.54) 0.520
60–69 1.30 (0.71–2.37) 0.399 1.36 (0.63–2.92) 0.465
�70 1.16 (0.61–2.21) 0.655 0.97 (0.42–2.20) 0.909
Gender
Female 1
Male 1.00 (0.67–1.49) 0.996 1.11 (0.71–1.74) 0.626
Marital Status
Single 1
Married 0.91 (0.46–1.84) 0.799 0.94 (0.40–2.21) 0.877
Divorced 0.75 (0.37–1.51) 0.423 0.90 (0.43–1.89) 0.781
Widowed 1.37 (0.80–2.33) 0.25 1.27 (0.68–2.37) 0.439
Family History
No 1
Yes 2.73 (1.00–7.44) 0.049 3.44 (0.09–0.88) 0.029
Presence of Comorbidities
No 1
Yes 1.27 (0.84–1.94) 0.262 1.29 (0.74–2.26) 0.734
Hypertension
No 1
Yes 1.31 (0.83–2.08) 0.244 1.11 (0.45–2.75) 0.734
Diabetes
No 1
Yes 1.17 (0.65–2.10) 0.597 0.74 (0.35–1.55) 0.512
Alcoholic intake
No 1
Yes 0.88 (0.42–1.81) 0.722 0.65 (0.25–1.69) 0.401
Smoking history
No 1
Yes 0.84 (0.34–2.06) 0.703 1.40 (0.42–4.69) 0.607
HR = Hazard Ratio, CI = Confidence Interval, P<0.05 = statistically significant.
https://doi.org/10.1371/journal.pone.0209307.t003
Colorectal cancer survival rates in Ghana
PLOS ONE | https://doi.org/10.1371/journal.pone.0209307 December 19, 2018 7 / 15
distant metastasis were significant prognostic factors on univariate analysis (p< 0.05). Late
stage tumours, Stage III [HR: 9.41(1.29–68.58), p = 0.027] and stage IV [HR: 12.89 (1.74–
95.24), p = 0.012)] were associated with poor survival. Similarly, T3 [(HR: 3.42 (1.05–11.11),
p = 0.041)] and T4 [(HR: 3.51(1.09–11.33) p = 0.036)], N stages, N1 [(HR: 2.65 (1.58–4.43),
p = 0.0001)] and N2 [(HR: 2.42(1.24–4.73), p = 0.009)] and M1 [(HR: 12.16(1.37–3.40),
P = 0.001)] were associated with poor survival. Tumour location and histological grade were
not statistically significant.
Discussion
Globally, there has been great improvement in colorectal cancer survival over the past decade
partly due to early detection and more effective treatments [20]. Howevever, CRC still remains
a major cause of mortality in developing countries. This study therefore investigated the sur-
vival rate of colorectal cancer and its prognostic factors among patients at the Komfo Anokye
Teaching Hospital, in Ghana.
In this study, the overall five year survival rate was 16%, which is extremely lower than the
typically reported survival rate in developed countries. A study by sankaranarayanan et al.,
(2011) on cancer survival in Africa, Asia, and Central America reported that, colorectal cancer
survival in Sub-Saharan African countries was extremely poor compared to Asian and central
Table 4. Association of clinical parameters with survival using cox regression analysis.
Univariate Analysis Multivariate Analysis
Variables HR 95% CI P-value HR 95% CI P-value
Duration of Symptoms
< 6 1
6–12 1.18 (0.671–2.057) 0.573 1.23 (0.78–1.93) 0.380
> 12 1.34 (0.759–2.379) 0.311 1.23 (0.62–2.26) 0.491
Surgery
No 1
Yes 1.11 (0.72–1.69) 0.648 3.82 (0.16–91.51) 0.408
Nature of Operation
Emergency 0.99 (0.63–1.58) 0.985 3.41 (0.14–82.49) 0.451
Elective 1
Chemotherapy
No 1
Yes 0.38 (0.25–0.57) 0.0001 0.23 (0.13–0.41) <0.0001
Radiotherapy
No 1
Yes 0.82 (0.51–1.32) 0.413 0.56 (0.20–1.60) 0.282
Both Chemo and Radiotherapy
No 1
Yes 0.87 (0.52–1.46) 0.596 3.63 (1.05–12.59) 0.042
BMI Categories
Normal 1
Underweight 1.74 (1.11–2.72) 0.016 1.78 (1.11–2.86) 0.017
Overweight 0.95 (0.51–1.75) 0.860 0.93 (0.48–1.78) 0.817
Obese 0.94 (0.46–1.89) 0.852 0.95 (0.46–1.98) 0.894
HR = Hazard ratio, CI = confidence interval, BMI = body mass Index, P<0.05 = statistically significant.
https://doi.org/10.1371/journal.pone.0209307.t004
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American countries. In sub-Saharan countries like the Gambia and Uganda, the survival was
less than 8% compared to 60% survival rate in Korea and this shows the huge variation in can-
cer survival between these two continents [21]. Lack of modernised infrastructure for cancer
care and unavailability of curative treatment for patients were some of the factors identified
for the poor cancer survival in Sub Saharan Africa. In Asian countries like China, colorectal
cancer patients have 60.8% survival rate after surgery. Studies from other developing countries
like Iran reported that the 5-year survival rates of colorectal cancer falls betweeen 27.2% and
61% [22] which are comparatively higher than our current finding.
Mostly, the stage of a cancer at diagnosis influences survival. For colorectal cancer stage,the
five-year survival rates varies from 90% for localized cancers, 70% for regional cancers, and
10% for distant metastatic cancers [1]. In this study, the overall survival rates based on CRC
TNM staging were 90% for stage I, 34% for stage II, 12% for stage III and 0.0% for stage IV
(Fig 3). The difference in survival rate among the different cancer stages using log rank test
was statistically significant (p = 0.0001). A study by Al-Ahwal et al., (2013) in Suadi Arabia
recorded 63.3% for patients with stage 1 cancers, 50.2% for those with stage 2&3 cancers, and
14.7% for patients stage 4 cancers which are slightly comparable to our findings [23], The
Table 5. Association of pathological parameters with survival using cox regression analysis.
Univariate Analysis Multivariate Analysis
Variables HR 95% CI P-value HR 95% CI P-value
Tumour Location
Colon 1
Rectum 0.99 (0.64–1.53) 0.965 0.86 (0.50–1.48) 0.592
Anorectum 0.41 (0.14–1.14) 0.088 0.40 (0.12–1.37) 0.144
Anal 1.12 (0.49–2.5) 0.79 2.15 (0.69–6.62) 0.183
More than one site 1.28 (0.49–3.28) 0.612 0.76 (0.22–2.64) 0.660
Histological Grade
Well differentiated 1
Moderately differentiated 1.62 (0.94–2.80) 0.085 1.33 (0.70–2.52) 0.377
Poorly differentiated 1.58 (0.77–3.55) 0.229 1.01 (0.35–2.91) 0.986
Undifferentiated 1.66 (0.75–3.33) 0.193 1.56 (0.63–3.85) 0.338
Tumour Stage
Stage 1 1
Stage II 4.12 (0.55–30.84) 0.168 2.00 (0.16–25.79) 0.595
Stage III 9.41 (1.29–68.58) 0.027 4.97 (0.28–87.64) 0.274
Stage IV 12.89 (1.74–95.24) 0.012 13.34 (0.49–359.01) 0.123
Depth of Tumour Invasion
T2 1
T3 3.42 (1.05–11.11) 0.041 1.67 (0.37–7.61) 0.508
T4 3.51 (1.09–11.33) 0.036 1.93 (0.43–8.59) 0.389
Lymph Node Metastasis
N0 1
N1 2.65 (1.58–4.43) 0.0001 1.01 (0.25–4.08) 0.991
N2 2.42 (1.24–4.73) 0.009 0.71 (0.17–2.95) 0.641
Distant Metastasis
M0 1
M1 2.16 (1.37–3.40) 0.001 0.49 (0.11–2.18) 0.352
HR = Hazard Ratio, CI = confidence Interval, T = tumour depth, N = lymph node metastasis, M = distant metastasis, P<0.05 = statistically significant
https://doi.org/10.1371/journal.pone.0209307.t005
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lower survival rates observed in this study could be due to the lack of interventions such as
screening programmes and public education on cancer prevention, inaccessibility to special-
ised centers and lack of effective modernised diagnostic techniques for efficient diagnosis and
prognosis. Improved life expectancy accompanied with the adoption of sedentary lifestyle and
unhealthy dietary habits among Ghanaians have resulted in the rise in the incidence of various
cancer including colorectal cancer leading to the high demand for quality cancer care. Studies
have also shown that patients mostly present with late stage cancers that are mostly incurable
[16] therefore resulting in poorer treatment outcome for patients with colorectal cancers. Late
presentation could be due to lack of education on the signs and symptoms of colorectal cancer
among the populace, lack of screening programmes for early detection and the fact that most
people might be oblivious of the importance of early reporting to hospital for diagnosis and
treatment. With colorectal cancer, prognosis is mostly determined by the characteristics of the
tumour and some patients related factors. Knowledge of these prognostic factors could help
physicians immensely to improve clinical outcomes [24]. Family history was significantly asso-
ciated with improved survival (p = 0.036) in both the log rank test and the cox regression
model (Tables 1 and 3). This is consistent with findings from [25] who reported that patients
who have family history of colorectal cancer have overall improved survival compared to those
who developed that cancer due to lifestlye factors but not neccesarly due to heredity. The rea-
son could be that, patients with family histroy of the disease are aware of their risk factor, and
thus seek early medical intervension and treatments which improves their live expectancy as
compared to sporadic cases.
Fig 2. Overall 5 year’s survival function curve in colorectal cancer patients at KATH.
https://doi.org/10.1371/journal.pone.0209307.g002
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Numerous studies report on the role of patient’s gender as a prognostive factor in colorectal
cancer, but in most of these studies, gender palyed no significant role in predicting survival
[26–28] which is consistent with findings from our current study. In this study, age was not
identified as a prognostic factor for survival. This agrees with several other studies[29–31].
However, some other studies found age as prognostic factor for poor survival in older patients
than younger ones. [26, 28, 32], In keeping with Akhood et al., (2011), our study could not
approve a significant relationship between survival rate and marital status [33].
Chemotherapy as a treatment modality was significantly related to improved survival
whereas having chemo-radiotherapy or radio-chemotherapy was associated with poor survival
(Table 4). Most patients with stage III disease are administered chemotherapy after surgery
[34]. Such treatment mostly classified as “adjuvant" helps to improve disease outcome by
destroying microscopic cancer cells which could have accumulated and developed into larger
tumours. This combined therapy has been proven to be effective in enhancing survival by 15–
20%. [35]. This explanation supports our finding that chemotherapy is associated with
improved survival. A study by Kumar et al., (2015) in Oman found BMI and chemotherapy as
independent risk factors of CRC, this supports the findings in this study [36]. There have been
conflicting findings on the association between BMI and colorectal cancer survival. A recent
meta-analysis reported that being obese before diagnosis of CRC (BMI�30 kg/m2) was signifi-
cantly associated with poorer survival [37]. A retrospective study by Tang et al (2016) also
found that, being underweight before treatment was associated with an increase risk of death
whereas overweight and obesity were favourable prognostic factors for overall survival in met-
astatic cancer patients [38]. Similarly, our study found that being underweight after diagnosis
was significantly associated with poor survival whereas being overweight or obese was more
favourable. On the contrary, Boyle et al., (2013) reported, post diagnostic overweight or obesity
was associated with poorer survival in colorectal cancer patients [39]. There is a link between
obesity and numerous cancer incidences, but in terms of survival, studies have proposed that
increasing levels of insulin and insulin-like growth factors as well as increasing insulin
Fig 3. Cumulative survival of CRC based on the cancer stage.
https://doi.org/10.1371/journal.pone.0209307.g003
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resistance in obesity may negatively influence colorectal cancer survival. [40]. It is therefore
advisable that colorectal cancer patients maintain a healthy normal weight which will help to
improve their survival.
In this present study, the stage of tumor was associated with worse survival (Table 5). This is
consistent with several studies [13, 41] that have demonstrated that advanced tumour stage is a
prognostic factor associated with poor survival in patients with CRC. Findings from this study
showed that, the state of regional lymph node metastasis was a significant prognostic factor for
poor suvival, which concurs with findings observed by other studies [42, 43]. Cox proportional
hazard model in this current study revealed that, distant metastasis was significantly associated
with poor survival (Table 5). This finding is supported by many other studies [44, 45] which also
idenfied distance metastasis as a significant factor for poor survival. Other studies have observed a
significant relationship between extent of tumour infiltration and prognosis [44, 46], this trend
was also observed in this current study. The extent of tumour infiltration into the intestinal wall,
lymph nodes and distant organs strongly influences the survival prospects of colorectal cancer
patients and also forms the basis for staging as well as treatment options for patients. [9].
Information on some of the study subjects were unavailable because of the retrospective
nature of the study. Patients who were diagnosed and treated only at KATH were included in
this study, hence this may not be a true reflection of the situation in the entire population,
although almost all oncological cases from the Northen and Central sectors of Ghana are refer-
erd to KATH for management. Inspite of these limitations, the study has provided useful infor-
mation that can help to direct Ghana cancer control strategy inorder to improve cancer
survival and help health practitioners in the management of patients with colorectal cancer.
Conclusion
The survival rate of colorectal cancer is very low in Ghana. Significant clinical and pathological
prognostic factors were; family history, chemotherapy, both chemo and radiotherapy, BMI,
TNM tumour stage, Depth of tumour invasion, lymph node metastasis, distance metastasis.
Therefore, this study highlights the need for intensified public health education to promote
awareness about the signs and symptoms of colorectal cancer and comprehensive screening
programmes which will greatly improve survival through early detection. Furthermore, molec-
ular studies should be done to identify potential molecular markers for an improved and effec-
tive treatment in the Ghanaian population.
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